High mortality during tuberculosis retreatment at a Ghanaian tertiary center: a retrospective cohort study
Tara C. Bouton, Audrey Forson, Samuel Kudzawu, Francisca Zigah, Helen E. Jenkins, Tsigereda Danso Bamfo, Jane Carter, Karen R. Jacobson, et al. (9 authors)
Pan African Medical Journal · 2019-01
Abstract
INTRODUCTION: High mortality among individuals receiving retreatment for tuberculosis (RT-TB) persists, although reasons for these poor outcomes remain unclear. METHODS: We retrospectively reviewed 394 RT-TB patients diagnosed between January 2010 and June 2016 in Accra, Ghana. RESULTS: Of RT-TB patients, 161 (40.9%) were treated empirically (negative/absent smear, culture or Xpert), of whom 30.4% (49/161) had only extrapulmonary TB signs or symptoms. Mortality during treatment was 19.4%; 15-day mortality was 10.8%. In multivariable proportional hazards regression, living with HIV (aHR=2.69 [95 CI: 1.51, 4.80], p<0.01) and previous loss-to-follow up (aHR=8.27 (95 CI: 1.10, 62.25), p=0.04) were associated with mortality, while drug susceptibility testing (DST, aHR=0.36 (95 CI: 0.13, 1.01), p=0.052) was protective. Isoniazid resistance was observed in 40% (23/58 tested) and rifampin resistance in 19.1% (12/63 tested). CONCLUSION: High rates of extrapulmonary TB and smear/culture negative disease highlight the barriers to achieving DST-driven RT-TB regimens and the need for improved diagnostics. Our finding of poly-drug resistance in rifampin-susceptible cases supports access to comprehensive first line DST. Additionally, interventions to reduce mortality, especially in HIV co-infected RT-TB patients, are urgently needed.
MeSH terms
- Medicine
- Tuberculosis
- Internal medicine
- Retrospective cohort study
- Isoniazid
- Drug resistance
- Extrapulmonary tuberculosis
- Mortality rate
- Extensively drug-resistant tuberculosis
- Cohort
- Culture conversion
- Human immunodeficiency virus (HIV)
- Proportional hazards model
- Mycobacterium tuberculosis